EPS Bio Technology

EPS Bio Technology FCF/Debt

The Free Cash Flow to Debt Ratio of EPS Bio Technology (4183.TWO) as of Oct 18, 2026 is -301.11 %. In the previous year, Free Cash Flow to Debt Ratio was -42.45 % — a change of 609.40% (lower).

FCF/Debt

-301.11 %

YoY

609.40%

Last updated:

Free Cash Flow to Debt Ratio of EPS Bio Technology is 2025 -301.11 % . Free Cash Flow to Debt Ratio of EPS Bio Technology was 2024 -42.45 % . It decreases by 609.40% lower compared to the previous year.

The EPS Bio Technology FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-10.60 TWD
Jan 1, 2019
23.59 TWD
Jan 1, 2020
55.27 TWD
Jan 1, 2021
15.77 TWD
Jan 1, 2022
-8.20 TWD
Jan 1, 2023
39.45 TWD
Jan 1, 2024
-42.45 TWD
Jan 1, 2025
-301.11 TWD
The EPS Bio Technology FCF/Debt history
YEARFCF/DebtYoY
-301.11 %+609.40%
-42.45 %-207.58%
39.45 %-581.14%
-8.20 %-152.00%
15.77 %-71.47%
55.27 %+134.34%
23.59 %-322.51%
-10.60 %-110.81%
98.02 %-7.81%
106.33 %-14.15%
123.85 %-598.42%
-24.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

EPS Bio Technology Stock analysis

What does EPS Bio Technology do? EPS Bio Technology Corp, listed on the Taiwan Stock Exchange with ticker 4183.TWO and ISIN TW0004183009, is headquartered in Baoshan, Taiwan. The company operates within the Health Care sector, specifically in the Health Care industry. It has a workforce of 123 employees. EPS Bio Technology Corp completed its initial public offering (IPO) on November 13, 2012. The company's primary business activities involve the development and manufacture of blood glucose monitoring systems, as well as the development and sales of various medical and related medical equipment. Its main product lines include blood glucose testers, blood glucose test strips, and electric breast pumps. The firm primarily distributes its products to international markets, with a focus on Europe, North America, and other regions in Asia. The company's official website is http://www.epsbio.com.tw/. EPS Bio Technology Corp does not disclose specific financial figures or additional details about its operations beyond the provided information. The company is based in Baoshan, Hsinchu, though the source description mentions Hsinchu as the headquarters location, which is consistent with the city provided in the data. The company's operations are centered around medical technology, with an emphasis on diagnostic and consumer health products. EPS Bio Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EPS Bio Technology stock

Free Cash Flow to Debt Ratio of EPS Bio Technology is -301.11 % in 2025.

Free Cash Flow to Debt Ratio of EPS Bio Technology changed from -42.45 % to -301.11 %, representing a 609.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio EPS Bio Technology since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's EPS Bio Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — EPS Bio Technology

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — EPS Bio Technology